Featured News

Showcasing the “brightest ideas and breakthroughs in digestive disease,” DDW 2020 includes recent studies and innovations in celiac disease and gluten-related disorders, some of which we have curated and summarized for you.

People with celiac disease have a small but significantly increased mortality rate. The finding comes from the largest study of its kind, which used long-term health records of celiac patients in Sweden between 1969 and 2017.

Dr. Dan Leffler, Celiac Disease Foundation Medical Advisory Board Member and clinician and researcher at Harvard Medical School and Takeda, spoke about the profound ineffectiveness and failure of the gluten-free diet as a treatment for celiac disease.

Our valued sponsors and vendors are committed to providing gluten-free products in this time of need.

Data from the Nexvax2 study shows celiac patients exposed to gluten react within two hours and experience nausea and vomiting, not the classic lower digestive symptoms commonly associated with celiac disease.

A group of celiac patients and caregivers from all 50 states will convene in Washington, DC to hear from researchers, federal government representatives, and celiac advocates for a National Patient Advocacy Summit to learn how to become Celiac Disease Foundation State Advocacy Ambassadors.

The Celiac Disease Foundation, the nation’s leading disease advocacy organization for celiac disease, announces the appointment of officers to its Board of Directors.

On December 11, 2019, CEO Marilyn G. Geller was with Senator Blumenthal's legislative staff as Senator Richard Blumenthal (D-CT) introduced S.3021: Gluten in Medicine Disclosure Act of 2019 to the Senate. The Celiac Disease Foundation is proud to be a partner in this effort.

After decades of pleading with our federal government to take celiac disease as seriously as it does other diseases with comparable patient impact, yesterday, the U.S. House and Senate each passed, and President Trump has signed, the FY2020 Federal budget resolution.

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…